Previous 10 | Next 10 |
BioCorRx (OTCQB:BICX) received approval from an independent institutional review board to begin a phase 1 trial of its therapy BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder. Naltrexone is used to manage alcohol or opioid use disorder by re...
ANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has received Independent Instit...
Anaheim, California--(Newsfile Corp. - March 2, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that management will present at the Q1 Investor Summit, hosted by the Inve...
ANAHEIM, CA - ( NewMediaWire ) - February 14, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that it has completed its clinical trial agreement w...
ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO ...
ANAHEIM, CA - ( NewMediaWire ) - December 09, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appointment of Dr. Jie Shen to the Scientific Advisory ...
ANAHEIM, CA - ( NewMediaWire ) - November 24, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO and Director of BioC...
BioCorRx (OTCQB:BICX) has acquired a patent application from Calista Therapeutics. This IP complements the company’s current IP portfolio and may be used for improvements to current naltrexone formulations owned by the company or licensed to third parties for use with other molecu...
Patent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance ...
ANAHEIM, CA - ( NewMediaWire ) - November 16, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September ...
News, Short Squeeze, Breakout and More Instantly...
ANAHEIM, CA - ( NewMediaWire ) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2024, and...
ANAHEIM, CA - ( NewMediaWire ) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmace...
ANAHEIM, CA - ( NewMediaWire ) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on...